Who
Mark J. Foley
Director
Company insider
Files Form 4 as: Director, Glaukos; President & CEO, Revance Therapeutics; Director, Si-Bone; President and CEO, Zeltiq Aesthetics.
In numbers
- Trades disclosed
- 261
- Buys
- 3
- Sells
- 51
- Bought
- $1.3M
- Sold
- $31.4M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 27 Apr 2012
- Last trade
- 28 May 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 May 2026filed 23 Jun 2026 | GKOS Glaukosoption or derivative · Medical Devices | SEC FORM 4 Code A | —2,987 at $0.00 | filing |
| 28 May 2026filed 23 Jun 2026 | GKOS Glaukosoption or derivative · Medical Devices | SEC FORM 4 Code A | —2,987 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | GKOS GlaukosMedical Devices | SEC FORM 4 Code A | —1,878 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | GKOS Glaukosoption or derivative · Medical Devices | SEC FORM 4 Code A | —2,987 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | GKOS Glaukosoption or derivative · Medical Devices | SEC FORM 4 Code A | —2,987 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | GKOS GlaukosMedical Devices | SEC FORM 4 Code A | —1,878 at $0.00 | filing |
| 2 Jan 2026filed 7 Jan 2026 | GKOS GlaukosMedical Devices | SEC FORM 4 Code A | —1,168 at $0.00 | filing |
| 2 Jan 2026filed 7 Jan 2026 | GKOS GlaukosMedical Devices | SEC FORM 4 Code A | —1,168 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | GKOS Glaukosoption or derivative · Medical Devices | SEC FORM 4 Code A | —3,149 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | GKOS GlaukosMedical Devices | SEC FORM 4 Code A | —2,108 at $0.00 | filing |
| 26 Feb 2025filed 28 Feb 2025 | GKOS Glaukosoption or derivative · Medical Devices | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 26 Feb 2025filed 28 Feb 2025 | GKOS Glaukosoption or derivative · Medical Devices | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 26 Feb 2025filed 28 Feb 2025 | GKOS GlaukosMedical Devices | SEC FORM 4 Code M | $800K25,000 at $32.00 | filing |
| 26 Feb 2025filed 28 Feb 2025 | GKOS GlaukosMedical Devices | SEC FORM 4 Code M | $370K15,000 at $24.69 | filing |
| 26 Feb 2025filed 28 Feb 2025 | GKOS GlaukosMedical Devices | SEC FORM 4 Sold | $2.5M20,687 at $120.72 | filing |
| 6 Feb 2025filed 6 Feb 2025 | Revance Therapeutics | SEC FORM 4 Code D | —27,933 | filing |
| 6 Feb 2025filed 6 Feb 2025 | Revance Therapeutics | SEC FORM 4 Code A | —84,686 at $0.00 | filing |
| 6 Feb 2025filed 6 Feb 2025 | Revance Therapeutics | SEC FORM 4 Code D | —84,686 | filing |
| 4 Feb 2025filed 6 Feb 2025 | Revance Therapeutics | SEC FORM 4 Code U | $3.6M996,935 at $3.65 | filing |
| 4 Feb 2025filed 6 Feb 2025 | Revance Therapeutics | SEC FORM 4 Code U | $405K110,913 at $3.65 | filing |
News
Glaukos Expands Retinal Pipeline With RevOpsis Deal - Orange County Business JournalGKOS · ocbj.com · 19 Oct 2026Glaukos: IDose TR Plus Cataract Surgery Delivers Superior Eye Pressure Reduction In Phase 4 TrialGKOS · rttnews.com · 9 Oct 2026
0 headlines in the last 90 days name Mark J. Foley; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.